Urovant Sciences (UROV) Tops Q1 EPS by 40c

Urovant Sciences (NASDAQ: UROV) reported Q1 EPS of ($0.99), $0.40 better than the analyst estimate of ($1.39).

“We continued to make important progress in the first fiscal quarter of 2020. We significantly enhanced the commercial and market access capabilities we need to successfully launch vibegron,” said James Robinson, president and chief executive officer of Urovant Sciences. “In addition, we continue to maximize the value of vibegron and have completed enrollment in our Phase 2a study of vibegron for IBS pain, an indication for which there are no currently marketed drugs.”

For earnings history and earnings-related data on Urovant Sciences (UROV) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• Evogene chairman to address dissident shareholders on results call